Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

ProMIS Neurosciences Inc. - Common Shares (NQ:PMN)

17.93 +2.14 (+13.55%)
Streaming Delayed Price Updated: 3:59 PM EST, Feb 24, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 64,603
Open 16.00
Bid (Size) 17.76 (100)
Ask (Size) 17.96 (200)
Prev. Close 15.79
Today's Range 15.91 - 17.96
52wk Range 6.270 - 39.75
Shares Outstanding 32,689,190
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
ProMIS Neurosciences to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
From ProMIS Neurosciences Inc.
Via GlobeNewswire
There are notable gap-ups and gap-downs in today's session. ↗
Via Chartmill

Performance

YTD
+151.3%
+151.3%
1 Month
+99.9%
+99.9%
3 Month
+119.9%
+119.9%
6 Month
+34.2%
+34.2%
1 Year
-10.4%
-10.4%

More News

Read More
Which stocks are moving before the opening bell on Friday? ↗
Via Chartmill
News headline image
ProMIS Neurosciences Announces Up to $175 Million Private Placement Financing
From ProMIS Neurosciences Inc.
Via GlobeNewswire
News headline image
ProMIS Neurosciences Exceeds Target Enrollment in PRECISE-AD Phase 1b Clinical Trial of PMN310 in Alzheimer’s Disease
From ProMIS Neurosciences Inc.
Via GlobeNewswire
News headline image
ProMIS Neurosciences Announces New Peer-Reviewed Publication Highlighting Selective Targeting of Toxic Oligomers for Potential Clinical Benefit and Reduced ARIA Risk
From ProMIS Neurosciences Inc.
Via GlobeNewswire
News headline image
ProMIS Neurosciences Announces New Peer-Reviewed Publication Showing Plasma pTau as a Predictive Early Endpoint in Alzheimer’s trials, Supporting its Ongoing Phase 1b PRECISE-AD trial with PMN310
From ProMIS Neurosciences Inc.
Via GlobeNewswire
News headline image
ProMIS Neurosciences to Participate in the 8th Annual Evercore Healthcare Conference
From ProMIS Neurosciences Inc.
Via GlobeNewswire
News headline image
Which stocks are experiencing notable movement on Monday? ↗
Via Chartmill
News headline image
Top movers in Monday's session ↗
Via Chartmill
News headline image
The market is filled with gapping stocks in Monday's session. ↗
Via Chartmill
News headline image
Wondering what's happening in today's pre-market session? ↗
Via Chartmill
News headline image
ProMIS Neurosciences Announces Reverse Stock Split
From ProMIS Neurosciences Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
Via Benzinga
News headline image
ProMIS Neurosciences Announces Third Quarter 2025 Financial Results & Corporate Highlights
From ProMIS Neurosciences Inc.
Via GlobeNewswire
News headline image
ProMIS Neurosciences to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference
From ProMIS Neurosciences Inc.
Via GlobeNewswire
News headline image
ProMIS Neurosciences Strengthens Board with Appointment of Slanix Paul Alex, Pharm.D., President and Portfolio Manager, Public Equity of Ally Bridge Group
From ProMIS Neurosciences Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Friday's After-Market Session ↗
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
Via Benzinga
News headline image
ProMIS Neurosciences Receives DSMB Approval to Advance to Final Dose Escalation Cohort in Phase 1b Alzheimer’s Trial of PMN310
From ProMIS Neurosciences Inc.
Via GlobeNewswire
News headline image
ProMIS Neurosciences Announces Second Quarter 2025 Financial Results & Corporate Highlights
From ProMIS Neurosciences Inc.
Via GlobeNewswire
News headline image
EXCLUSIVE: July's 20 Most-Searched Tickers On Benzinga Pro — Where Do Opendoor, Nvidia, Apple Stock Rank? ↗
Via Benzinga
News headline image
ProMIS Neurosciences to Showcase Protein-Misfolding Drug Discovery Platform & PRECISE-AD Trial Design at the 2025 Alzheimer’s Association International Conference
From ProMIS Neurosciences Inc.
Via GlobeNewswire
News headline image
What's going on in today's pre-market session ↗
Via Chartmill
News headline image
ProMIS Neurosciences Announces Private Placement Financing
From ProMIS Neurosciences Inc.
Via GlobeNewswire

Frequently Asked Questions

Is ProMIS Neurosciences Inc. - Common Shares publicly traded?
Yes, ProMIS Neurosciences Inc. - Common Shares is publicly traded.
What exchange does ProMIS Neurosciences Inc. - Common Shares trade on?
ProMIS Neurosciences Inc. - Common Shares trades on the Nasdaq Stock Market
What is the ticker symbol for ProMIS Neurosciences Inc. - Common Shares?
The ticker symbol for ProMIS Neurosciences Inc. - Common Shares is PMN on the Nasdaq Stock Market
What is the current price of ProMIS Neurosciences Inc. - Common Shares?
The current price of ProMIS Neurosciences Inc. - Common Shares is 17.93
When was ProMIS Neurosciences Inc. - Common Shares last traded?
The last trade of ProMIS Neurosciences Inc. - Common Shares was at 02/24/26 03:59 PM ET
What is the market capitalization of ProMIS Neurosciences Inc. - Common Shares?
The market capitalization of ProMIS Neurosciences Inc. - Common Shares is 586.12M
How many shares of ProMIS Neurosciences Inc. - Common Shares are outstanding?
ProMIS Neurosciences Inc. - Common Shares has 586M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.